Phentermine
From Order Phentermine
Phentermine Online Information Center
Cheap Phentermine
Phentermine was first approved by the Food and Drug Administration (FDA) in
|
In 1959 phentermine first received approval from the FDA as an appetite suppressing drug. Phentermine hydrochloride then became available in the early 1970s. It was previously sold as Fastin® from King Pharmaceuticals for SmithKline Beecham, however in 1998 it was removed from the market. Medeva Pharmaceuticals sells the name brand of phentermine called Ionamin® and Gate Pharmaceuticals sells it as Phentermine. Cheap Phentermine it belong to a class of medicine called amphetamines. Amphetamines are concentrated in the kidney, lungs, cerebrospinal fluid and brain. Cheap Phentermine is a prescription medication used to curb appetite. Phentermine is recommended for people who are seriously overweight, not those who simply want to lose a few pounds. Given the few long-term studies on phentermine, it's approved only for short-term use (a few weeks). Unfortunately, any weight lost during this time is usually regained. Phentermine side effects may include blurred vision, dry mouth, sleeplessness, irritability and constipation. Phentermine is also currently sold as a generic. Phentermine also increases heart rate and blood pressure. Phentermine is rapidly absorbed after oral ingestion. Don't take phentermine if you have certain medical conditions, including heart disease, high blood pressure, an overactive thyroid gland, glaucoma or diabetes.Cheap Phentermine is a short term weight loss aid in conjunction with proper diet and exercise. If you are looking to loose weight, Phentermine can be a good solution for you, and you just can find the right pharmacy to buy generic phentermine. If your doctor prescribes phentermine, it should be part of an overall weight-loss plan that includes healthy eating and regular exercise. Remember, lasting weight loss requires permanent changes to your eating and exercise habits.
Phentermine
Phentermine was shown in the 1970s to inhibit the metabolism of serotonin by monoamine oxidase (MAO), but never was labeled as an MAO inhibitor; hence, it was widely used in combination with fenfluramine, and continues to be used, in violation of their labels, with other serotonin uptake blockers. We examined the effects of phentermine and several other unlabeled MAO inhibitors on MAO activities in rat lung, brain, and liver, and also the interactions of such drugs when administered together. Rat tissues were assayed for MAO-A and -B, using serotonin and b-phenylethylamine as substrates. Phentermine inhibited serotoninmetabolizing (MAO-A) activity in all three tissues with Ki values of 85–88 mM. These potencies were similar to those of the antidepressant MAO inhibitors iproniazid and moclobemide. When phentermine was mixed with other unlabeled reversible MAO inhibitors (e.g. pseudoephedrine, ephedrine, norephedrine; estradiol benzoate), the degree of MAO inhibition was additive. The cardiac valvular lesions and primary pulmonary hypertension that have been reported to be associated with fenfluramine-phentermine use may have resulted from the intermittent concurrent blockage of both serotonin uptake and metabolism. The anorexigen fenfluramine and its dextro-isomer dexfenfluramine have been implicated in the development of echocardiographically defined cardiac valvular disease. Initial open-label observations were interpreted as showing that as many as 30% of patients who took one of these drugs would develop such disease; however, subsequent controlled studies indicate that it occurs much less frequently, and in most cases is asymptomatic. Dexfenfluramine, which enhances serotonin-mediated neurotransmission by blocking serotonin reuptake and, through its nordexfenfluramine metabolite, directly releasing the transmitter and activating postsynaptic serotonin -2A and -2C receptors, had been used for many years outside the United States, without apparent association with valvular lesions; similarly, fenfluramine had been prescribed for three decades without generating known valvular pathology. Hence, we wondered whether the occurrence of apparent valve damage in the United States might have been related partly to the widespread, peculiarly American practice of taking fenfluramine along with another anorexigen, phentermine. Phentermine, like fenfluramine but not dexfenfluramine, is a generic drug; it is usually described as a “sympathomimetic amine,” implying a primary action on noradrenergic neurotransmission. We examined its effects in rats, and found that it releases brain dopamine, so we conducted additional studies to see whether it also raised blood dopamine levels in humans. After a single oral therapeutic phentermine dose (15 or 30 mg), plasma dopamine levels did rise significantly; however, levels of serotonin within blood platelets increased by an even greater proportion. Since there was no concurrent rise in plasma serotonin levels, the increase in platelet serotonin most likely reflected a slowed degradation of the amine, and not an increase in its uptake from the plasma.